Evidence map›Paper›PMID 34117268›Full record

ArticleNPJ Parkinson's disease2021

Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study.

Bruna Meira, Bertrand Degos, Elise Corsetti, Mohamed Doulazmi, Emeline Berthelot, Clara Virbel-Fleischman, Pauline Dodet, Aurélie Méneret, Louise-Laure Mariani, Cécile Delorme and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Device aided therapies in Parkinson disease: an expert view on apomorphine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Advanced therapies in Parkinson's disease: an individualized approach to their indication.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 3 countries.

Bruna MeiraNeurology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
Bertrand DegosNeurology Department, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France.
Elise CorsettiNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Mohamed DoulazmiAdaptation Biologique et Vieillissement, Institut de Biologie Paris Seine, Sorbonne University, CNRS, Paris, France.
Emeline BerthelotNeurology Department, Hôpital Zobda Quitman, Fort-de-France, French West Indies, France.
Clara Virbel-FleischmanAir Liquide SA, Explor Center (Healthcare), Fort-de-France, Paris, France.ORCID http://orcid.org/0000-0002-3951-4653
Pauline DodetParis Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France.
Aurélie MéneretNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Louise-Laure MarianiNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Cécile DelormeNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Florence Cormier-DequaireNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
David BendetowiczNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.ORCID http://orcid.org/0000-0002-6310-1250
Nicolas VillainNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Clément TarranoNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Lise MantisiNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Hélène LetrillartNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Céline LouapreNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Eavan McGovernNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Yulia WorbeNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
David GrabliNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Marie VidailhetNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Elodie HainqueNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Emmanuel RozeNeurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France. emmanuel.flamand-roze@aphp.fr.ORCID http://orcid.org/0000-0001-9727-3459
Centre National de la Recherche Scientifique · FRSorbonne Université · FRCentro Hospitalar de Lisboa Ocidental · PTUniversité Sorbonne Paris Nord · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term effects of continuous subcutaneous apomorphine infusion (CSAI) on health-related quality of life (HRQoL) and predictors of CSAI discontinuation are poorly known. Data from consecutive advanced Parkinson's disease patients treated in routine care were retrospectively collected over 24 months after CSAI initiation, with a focus on the 39-item Parkinson's disease questionnaire (PDQ-39). We determined predictors of CSAI discontinuation and HRQoL improvement using multiple regression analysis. Of the 110 subjects evaluated over a 2-year period, 35% discontinued CSAI. Of those who continued treatment, HRQoL remained stable with a sustained reduction in motor fluctuations. The observed effect on dyskinesias was mild and transient. Of note, patients with preexisting impulse control disorders showed an overall good tolerability. PDQ-39 was the only baseline predictor of HRQoL improvement after 2 years of treatment. The presence of dyskinesias, poorer psychological status, shorter disease duration, male sex, and worse OFF state were predictors of discontinuation. Best candidates for CSAI are patients with: (i) poor baseline HRQoL and (ii) marked motor fluctuations.

Identifiers

PMID34117268
PMCPMC8196159
OpenAlexW3167513901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.